Prognostic factors for disease-free survival in patients with pancreatic ductal adenocarcinoma after surgery: a single center experience
Journal of Pancreatology · 2019
DOI: 10.1097/jp9.0000000000000011 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Pancreatology, 2019. Verfasst von Xiaodong Tian und 7 weiteren Autor:innen. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Objective
To evaluate the risk factors for the disease-free survival (DFS) of pancreatic ductal adenocarcinoma (PDAC) patients after surgery, and to validate the clinical applicability and prognostic stratification of the 8th edition American Joint Committee on Cancer (AJCC) staging system.
Methods
A cohort of 185 patients with PDAC who underwent surgical resection in the General Surgery Department of Peking University First Hospital from January 2010 to December 2017 was enrolled retrospectively. The clinicopathological characteristics and survival data were analyzed to find out risk factors correlated to DFS. The survival curves were calculated according to the 8th edition of AJCC staging system.
Results
Among the 185 PDAC patients, 125 (67.6%) with pancreatic head carcinoma underwent pancreatoduodenectomy or total pancreatectomy, and 60 (32.4%) with tumors located in the pancreatic body and tail underwent distal pancreatectomy and splenectomy. R0 resection was achieved in 97 patients (52.4%), and the R1 and R2 resections rate was 44.9% and 2.7%, respectively. One hundred five patients (56.8%) received postoperative adjuvant chemotherapy. The median overall survival (OS) was 21 (95% confidence interval [CI] 17.7–24.3) months, and median DFS was 15 (95% CI 13.6–16.5) months. Univariate analysis showed that AJCC T and N staging, status of resection margin, grade of tumor differentiation, perineural invasion, intravascular cancer embolus, combined vascular resection, neutrophil-to-lymphocyte ratio (NLR) ≥ 2, carcinoembryonic antigen ≥5 ng/mL, carbohydrate antigen 19-9 (CA 19-9) ≥ 400 U/mL, and without postoperative adjuvant chemotherapy were correlated with shorter DFS. Furthermore, AJCC T3, N1 and N2 staging, R2 resection, low-grade or undifferentiated tumors, combined vascular resection, NLR ≥ 2, CA 19-9 ≥ 400 U/mL, and without postoperative adjuvant chemotherapy were independent risk factors for DFS. Both the DFS and OS curves were well separated by stage using the 8th staging classification.
Conclusions
The 8th edition of AJCC T, primary tumor; N, regional lymph nodes; M, distant metastasis staging system could predict the prognosis of PDAC accurately. Patients with AJCC T3, N1 and N2 staging, R2 resection, low-grade or undifferentiated tumors, combined vascular resection, NLR ≥ 2, CA 19-9 ≥ 400 U/mL, and without postoperative adjuvant chemotherapy, have a significantly higher risk of tumor recurrence and shorter DFS after surgery. R0 resection and adjuvant chemotherapy could significantly prolong the DFS of PDAC patients.
Zitieren
APA
Tian, X., Li, J., Gao, H., Zhuang, Y., Ma, Y., Chen, Y., Xie, X., & Yang, Y. (2019). Prognostic factors for disease-free survival in patients with pancreatic ductal adenocarcinoma after surgery: a single center experience. Journal of Pancreatology. https://doi.org/10.1097/jp9.0000000000000011
Vancouver
Tian X, Li J, Gao H, Zhuang Y, Ma Y, Chen Y, et al. Prognostic factors for disease-free survival in patients with pancreatic ductal adenocarcinoma after surgery: a single center experience. Journal of Pancreatology. 2019. doi:10.1097/jp9.0000000000000011
BibTeX
@article{Tian2019,
author = {Tian, Xiaodong and Li, Jisong and Gao, Hongqiao and Zhuang, Yan and Ma, Yongsu and Chen, Yiran and Xie, Xuehai and Yang, Yinmo},
title = {Prognostic factors for disease-free survival in patients with pancreatic ductal adenocarcinoma after surgery: a single center experience},
journal = {Journal of Pancreatology},
year = {2019},
doi = {10.1097/jp9.0000000000000011}
}
EUVIMED